Unsustained complete response of less than 24 months after autologous stem cell transplantation predicts aggressive myeloma with short survival.

about

Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response.

P2860

Q48338656-6BE850F0-6985-433A-81FA-9EC9617A2B3D

P2860

Unsustained complete response of less than 24 months after autologous stem cell transplantation predicts aggressive myeloma with short survival.

Item

http://www.wikidata.org/entity/Q53095991

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Unsustained complete response ...... e myeloma with short survival.

@en

Unsustained complete response ...... e myeloma with short survival.

@nl

type

Item

label

Unsustained complete response ...... e myeloma with short survival.

@en

Unsustained complete response ...... e myeloma with short survival.

@nl

prefLabel

Unsustained complete response ...... e myeloma with short survival.

@en

Unsustained complete response ...... e myeloma with short survival.

@nl

P1476

Unsustained complete response ...... ve myeloma with short survival

@en

P2093

Albert Kwok Wai Lie

http://www.w3.org/2001/XMLSchema#string

Eric Yuk Tat Chan

http://www.w3.org/2001/XMLSchema#string

Herman Liu

http://www.w3.org/2001/XMLSchema#string

Michael Wong

http://www.w3.org/2001/XMLSchema#string

Sandy Ho

http://www.w3.org/2001/XMLSchema#string

Yok Lam Kwong

http://www.w3.org/2001/XMLSchema#string

P2860

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma.

International staging system for multiple myeloma.

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.

Restoration of chemosensitivity by bortezomib: implications for refractory myeloma.

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.

The role of complete response in multiple myeloma.

Importance of achieving a complete response in multiple myeloma, and the impact of novel agents.

P304

205-211

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HON.2131

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

CS Chim

P577

2014-01-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24473998

http://www.w3.org/2001/XMLSchema#string

Unsustained complete response of less than 24 months after autologous stem cell transplantation predicts aggressive myeloma with short survival.

about

P2860

P2860

Unsustained complete response of less than 24 months after autologous stem cell transplantation predicts aggressive myeloma with short survival.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698